First Asset Match auction nearing close

​

Tissue Regenix Group Ltd

('Tissue Regenix', the 'Group', or the 'Company')

First Asset Match auction nearing close

Tissue Regenix Group Ltd, the regenerative medical devices company, announces that the first Asset Match auction for the trading of Tissue Regenix shares is due to close on 24 February 2026. On the final day before the auction, and once orders on both sides of the book have been received, shareholders registered with Asset Match will be emailed the current indicative price and instructions on how to participate.

Following the Cancellation from trading on AIM, Tissue Regenix appointed Asset Match to facilitate trading in the Ordinary Shares. Asset Match, a firm authorised and regulated by the Financial Conduct Authority ((FRN 579310), operates an electronic off-market dealing facility for the Ordinary Shares, allowing existing holders of Ordinary Shares in the Company ("Shareholders") and new investors to trade Ordinary Shares by matching buyers and sellers through periodic auctions.

Asset Match operates an open auction system where volumes of bids and offers at different prices are displayed on its website together with the closing date of the auction. At the end of each auction period, Asset Match passes this information through a non-discretionary algorithm that determines a "market-derived" share price based on supply and demand and allocates transactions accordingly. Bids and offers may be made and withdrawn at any time before the closing date of each auction.

Shareholders wishing to trade shares through Asset Match must do so through a stockbroker. A comprehensive list of stockbrokers who have signed up to access the Asset Match platform is available on request by emailing [email protected]. Shareholders may contact Asset Match in relation to any queries regarding trading via the secondary market trading facility by emailing [email protected].

For more information, please contact:

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.